0000899243-22-026190.txt : 20220715
0000899243-22-026190.hdr.sgml : 20220715
20220715204609
ACCESSION NUMBER: 0000899243-22-026190
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220713
FILED AS OF DATE: 20220715
DATE AS OF CHANGE: 20220715
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jones Anne
CENTRAL INDEX KEY: 0001869584
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38914
FILM NUMBER: 221087977
MAIL ADDRESS:
STREET 1: C/O CELULARITY INC.
STREET 2: 170 PARK AVENUE
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celularity Inc
CENTRAL INDEX KEY: 0001752828
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831702591
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 PARK AVE
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (908) 768-2170
MAIL ADDRESS:
STREET 1: 170 PARK AVE
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
FORMER COMPANY:
FORMER CONFORMED NAME: GX Acquisition Corp.
DATE OF NAME CHANGE: 20180912
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-13
0
0001752828
Celularity Inc
CELU
0001869584
Jones Anne
C/O CELULARITY INC.
170 PARK AVENUE
FLORHAM PARK
NJ
07932
0
1
0
0
Chief Business Officer
Class A Common Stock
2022-07-13
4
A
0
11483
0.00
A
27888
D
Stock Option (Right to Buy)
10.16
2022-07-13
4
A
0
33670
0.00
A
2032-07-13
Class A Common Stock
33670
33670
D
These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs is subject to time-based vesting over a four-year period, with 25% vesting on the one-year anniversary of the grant date, and the remainder vesting in equal annual installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date.
This option was granted under the 2021 Plan and shall vest and become exercisable over a four-year period, with 25% of the option vesting on April 13, 2023, and the remainder vesting in equal monthly installments thereafter so that vested in full on April 13, 2026, and subject to the Reporting Person's continuous service on each vesting date.
/s/ Keary Dunn, Attorney-in-Fact
2022-07-15